Emerging biological treatments for asthma

Area of Science:

• Pulmonology and immunology
• Severe asthma pathogenesis
• Biologics in respiratory disease

Background:

• Severe asthma is a chronic airway disease with diverse endotypes.
• Existing biological therapies target specific pathways like IgE, IL-5, and IL-4/IL-13, improving quality of life.
• Patients with T2-low asthma often do not benefit from current biologics.

Purpose of the Study:

• To review current and emerging biological therapies for severe asthma.
• To highlight novel therapeutic targets for difficult-to-treat asthma phenotypes.
• To discuss the potential of targeting alarmins for all severe asthma patients.

Main Methods:

• Review of current literature on severe asthma biologics.
• Analysis of emerging therapeutic targets and their mechanisms.
• Focus on alarmin-targeting therapies and their clinical implications.

Main Results:

• Monoclonal antibodies targeting IgE, IL-5, and IL-4/IL-13 receptors are effective for T2-high asthma.
• Alarmins (TSLP, IL-25, IL-33) are key upstream mediators in asthma pathogenesis.
• Anti-alarmin therapies show promise as add-on treatments for T2-high asthma and potentially for T2-low asthma.

Conclusions:

• Biological therapies have transformed severe asthma management.
• Targeting alarmins represents a promising new strategy for severe asthma, potentially benefiting a broader patient population.
• Further research into anti-alarmin therapies is warranted for poorly controlled severe asthma.